Abstract
INTERVENTION: In the case group with zinc sulfate (1mg/kg/day) In the control group without zinc supplementation Intervention 1: In the case group with zinc sulfate (1mg/kg/day). Intervention 2: In the control group without zinc supplementation. Treatment ‐ Drugs
CONDITION: Urinary tract infection, site not specified Urinary tract infection. ; Urinary tract infection, site not specified
PRIMARY OUTCOME: Abdominal pain. Timepoint: 14 days after treatment (Daily 14 days) ‐ 7 to 10 days after the end of treatment ( Urine Culture). Method of measurement: Asking mother and child. Dysuria. Timepoint: 14 days after treatment (Daily 14 days) ‐ 7 to 10 days after the end of treatment ( Urine Culture). Method of measurement: Asking mother and child ‐ Results of urine tests. Fever. Timepoint: 14 days after treatment (Daily 14 days) ‐ 7 to 10 days after the end of treatment ( Urine Culture). Method of measurement: Asking mother and child ‐ Thermometer. Frequency. Timepoint: 14 days after treatment (Daily 14 days) ‐ 7 to 10 days after the end of treatment ( Urine Culture). Method of measurement: Asking mother and child ‐ Results of urine tests. Urinary Tract Infection. Timepoint: 14 days after treatment (Daily 14 days) ‐ 7 to 10 days after the end of treatment ( Urine Culture). Method of measurement: Asking mother and child ‐ Results of urine tests.
SECONDARY OUTCOME: Anorexia. Timepoint: 14 days after treatment. Method of measurement: Mother and child statement. Growth failure. Timepoint: 6 months after treatment. Method of measurement: Mother’s remarks. Weight loss. Timepoint: Three month after treatment. Method of measurement: Mother’s remarks.
INCLUSION CRITERIA: Female children 3 to 12 years old with UTI, without norogenic bladder, anatomical abnormalities, or any other malformations or kidney stones
Exclusion criteria: Lack of patient cooperation, inappropriate use of prescribed drugs, history of recurrent UTI, those who have been treated for their UTI with drugs other than Ceftriaxon and Cefoxim